Filing Flows › Kymera Therapeutics (KYMR) › Q2 2026 › vs Q2 2025
Kymera Therapeutics (KYMR) Q2 2026 vs Q2 2025 (year over year)
Kymera Therapeutics's revenue rose $53.5M (+466%) from $11.5M in Q2 2025 to $65.0M in Q2 2026.
Kymera Therapeutics, Q2 2026: revenue $65.0M (+466% year over year), operating margin -116.3%, net loss $61.2M, operating cash flow −$54.1M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $65.0M | $11.5M | $53.5M | +466% |
| Other income, net | $14.4M | $7.9M | $6.5M | +81% |
| Net loss | $61.2M | $76.6M | −$15.4M | -20% |
| Costs & expenses | $141M | $96.0M | $44.6M | +46% |
| Operating costs | $141M | $96.0M | $44.6M | +46% |
| Operating cash sources | $75.0M | $77.4M | −$2.4M | -3% |
| Depreciation & amortization | $2.0M | $2.1M | −$54K | -3% |
| Share-based compensation | $18.9M | $15.4M | $3.5M | +23% |
| Cash used in operations | $54.1M | $59.9M | −$5.8M | -10% |
| Net loss absorbed | $61.2M | $76.6M | −$15.4M | -20% |
| Working capital & other | $13.8M | $770K | $13.1M | 18× |
Questions
How much did Kymera Therapeutics's revenue grow year over year in Q2 2026?
Kymera Therapeutics's revenue rose $53.5M (+466%) from $11.5M in Q2 2025 to $65.0M in Q2 2026.